Free-wilson and structural approaches to Co-optimizing human and rodent isoform potency for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 23, 2012, Pages 10652-10661

  Goldberg, Frederick W ^a   Leach, Andrew G ^a   Scott, James S ^a   Snelson, Wendy L ^a   Groombridge, Sam D ^a   Donald, Craig S ^a   Bennett, Stuart N L ^a   Bodin, Cristian ^a   Gutierrez, Pablo Morentin ^a   Gyte, Amy C ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; ANTIDIABETIC AGENT; ENZYME INHIBITOR; GLUCOSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; DRUG ACTIVITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; GLYCEMIC INDEX; HUMAN; MALE; MOUSE; NONHUMAN; RAT; STRUCTURE ANALYSIS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, MOLECULAR;

EID: 84871019425     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3013163     Document Type: Article

References (20)

1. Ge, R.; Huang, Y.; Liang, G.; Li, X. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development Curr. Med. Chem. 2010, 17, 412-422
2. Morgan, S. A.; Tomlinson, J. W. 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes Expert Opin. Invest. Drugs 2010, 19, 1067-1076
3. Masuzaki, H.; Yasue, S.; Nakao, K. Molecular target of the metabolic syndrome. 11β-HSD1 an adipocyte function Card. Pract. 2005, 16, 179-186
4. Anagnostis, P.; Athyros, V. G.; Tziomalos, K.; Karagiannis, A.; Mikhailidis, D. P. The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis J. Clin. Endocrinol. Metab. 2009, 94, 2692-2701
5. Scott, J. S.; Bowker, S. S.; deSchoolmeester, J.; Gerhardt, S.; Hargreaves, D.; Kilgour, E.; Lloyd, A.; Mayers, R. M.; McCoull, W.; Newcombe, N. J.; Ogg, D.; Packer, M. J.; Rees, A.; Revill, J.; Schofield, P.; Selmi, N.; Swales, J. G.; Whittamore, P. R. O. Discovery of a Potent, Selective, and Orally Bioavailable Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor: Discovery of 2-[(3S)-1-[5-(Cyclohexylcarbamoyl)-6- propylsulfanylpyridin-2-yl]-3-piperidyl]acetic Acid (AZD4017) J. Med. Chem. 2012, 55, 5951-5964
6. Scott, J. S.; Gill, A. L.; Godfrey, L.; Groombridge, S. D.; Rees, A.; Revill, J.; Schofield, P.; Sörme, P.; Stocker, A.; Swales, J. G.; Whittamore, P. R. O. Optimisation of Pharmacokinetic Properties in a Neutral Series of 11β-HSD1 Inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 6756-6761
7. Free, S. M., Jr.; Wilson, J. W. A mathematical contribution to structure-activity studies J. Med. Chem. 1964, 7, 395-399
8. Freeman-Cook, K. D.; Amor, P.; Bader, S.; Buzon, L. M.; Coffey, S. B.; Corbett, J. W.; Dirico, K. J.; Doran, S. D.; Elliott, R. L.; Esler, W.; Guzman-Perez, A.; Henegar, K. E.; Houser, J. A.; Jones, C. S.; Limberakis, C.; Loomis, K.; McPherson, K.; Murdande, S.; Nelson, K. L.; Phillion, D.; Pierce, B. S.; Song, W.; Sugarman, E.; Tapley, S.; Tu, M.; Zhao, Z. Maximizing lipophilic efficiency: The use of free-wilson analysis in the design of inhibitors of acetyl-CoA carboxylase J. Med. Chem. 2012, 55, 935-942
9. Patel, Y.; Gillet, V. J.; Howe, T.; Pastor, J.; Oyarzabal, J.; Willett, P. Assessment of Additive/Nonadditive Effects in Structure-Activity Relationships: Implications for Iterative Drug Design J. Med. Chem. 2008, 51, 7552-7562
10. Thomas, M. P.; Potter, B. V. L. Crystal structures of 11β-hydroxysteroid dehydrogenase type 1 and their use in drug discovery Future Med. Chem. 2011, 3, 367-390
11. Walker, E. A.; Clark, A. M.; Hewison, M.; Ride, J. P.; Stewart, P. M. Functional Expression, Characterization, and Purification of the Catalytic Domain of Human 11-beta-Hydroxysteroid Dehydrogenase Type 1 J. Biol. Chem. 2001, 276, 21343-21350
12. Maser, E.; Voelker, B.; Friebertshaeuser, J. 11β-Hydroxysteroid Dehydrogenase Type 1 from Human Liver: Dimerization and Enzyme Cooperativity Support Its Postulated Role as Glucocorticoid Reductase Biochemistry 2002, 41, 2459-2465
13. Hosfield, D. J.; Wu, Y.; Skene, R. J.; Hilgers, M.; Jennings, A.; Snell, G. P.; Aertgeerts, K. Conformational Flexibility in Crystal Structures of Human 11{beta}-Hydroxysteroid Dehydrogenase Type I Provide Insights into Glucocorticoid Interconversion and Enzyme Regulation J. Biol. Chem. 2005, 280, 4639-4648
14. Favia, A. D.; Masetti, M.; Recanatini, M.; Cavalli, A. Substrate Binding Process and Mechanistic Functioning of Type 1 11β-Hydroxysteroid Dehydrogenase from Enhanced Sampling Methods PLoS ONE 2011, 6, e25375
15. Zhang, J.; Osslund, T. D.; Plant, M. H.; Clogston, C. L.; Nybo, R. E.; Xiong, F.; Delaney, J. M.; Jordan, S. R. Crystal Structure of Murine 11β-Hydroxysteroid Dehydrogenase 1: An Important Therapeutic Target for Diabetes‡ Biochemistry (N. Y.) 2005, 44, 6948-6957
16. Maestro; Schrödinger, LLC: New York, NY, 2011; 9.2.
17. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248
18. Waring, M. J. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability Bioorg. Med. Chem. Lett. 2009, 19, 2844-2851
19. Kotelevtsev, Y.; Brown, R. W.; Fleming, S.; Kenyon, C.; Edwards, C. R. W.; Seckl, J. R.; Mullins, J. J. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2 J. Clin. Invest. 1999, 103, 683-689
20. Veniant, M. M.; Hale, C.; Komorowski, R.; Chen, M. M.; St., J., D. J.; Fotsch, C.; Wang, M. Time of the day for 11β-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice Diabetes, Obes. Metab. 2009, 11, 109-117